Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have heart- and kidney-related benefits for patients with and without diabetes that go beyond their initial indication for lowering blood sugar levels.
Study highlights safety concerns of SGLT2i in patients with diabetes and cancer
- Post author:
- Post published:November 2, 2023
- Post category:uncategorized